approval

Impact of COVID-19 on Regulatory Enforcement and Approvals

The impacts of the COVID-19 pandemic bring change shifts the status quo on a daily basis with both breadth and depth. Everything we as individuals and as a society would normally do is undergoing change. FDA regulatory oversight is one … Continue reading




approval

Impact of COVID-19 on Regulatory Enforcement and Approvals – Part 2

Earlier this month I published a blog posting that raised questions related to the potential for disruption of approvals in the wake of FDA actions to limit inspections due to the COVID-19 pandemic. Subsequently I had the opportunity to pose … Continue reading




approval

Impact of COVID-19 on Regulatory Enforcement and Approvals – Part 3 – FDA Adds Resources to Facilitate COVID-19 Research

With the COVID-19 impact making itself apparent on a daily basis as the numbers climb and organizations respond, the effects on the pharma and biotech sector also shifts. Yesterday FDA announced a new concentration of agency assets to be focused … Continue reading




approval

Impact of COVID-19 on FDA Enforcement and Approvals – Part 5 – FDA Provides Update to Shape Expectations on New Approvals

In response to written questions submitted last month regarding the potential for delays, FDA had stated that “CDER remains fully capable to continue daily activities, while responding to the public needs of the current COVID-19 outbreak.” In a subsequent blog … Continue reading




approval

COVID-19 Pandemic Likely to Affect FDA Product Approval Timelines

April 27, 2020 – As the COVID-19 pandemic continues, the Food and Drug Administration (FDA) must balance safeguarding public health with the desire for timely product reviews. Staff members at the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research are working diligently to keep all of these balls in […]




approval

EMA starts reviewing Gilead's remdesivir data to accelerate approval of COVID-19 antiviral

The European Medicines Agency has begun a rolling review of data on Gilead’s remdesivir, positioning it to cut the time it takes to decide whether to approve the drug in COVID-19 patients.




approval

FDA delays decision on approval of Bristol Myers' CAR-T

The FDA has delayed its decision on whether to approve Bristol Myers Squibb’s CAR-T cell therapy by three months. Bristol Myers attributed the delay to its submission of additional information upon the request of the FDA.




approval

Why legislative proposals to improve drug and device development must look beyond FDA approvals


Legislative proposals to accelerate and improve the development of innovative drugs and medical devices generally focus on reforming the clinical development and regulatory review processes that occur before a product gets to market. Many of these proposals – such as boosting federal funding for basic science, streamlining the clinical trials process, improving incentives for development in areas of unmet medical need, or creating expedited FDA review pathways for promising treatments – are worthy pursuits and justifiably part of ongoing efforts to strengthen biomedical innovation in the United States, such as the 21st Century Cures initiative in the House and a parallel effort taking shape in the Senate.

What has largely been missing from these recent policy discussions, however, is an equal and concerted focus on the role that postmarket evidence can play in creating a more robust and efficient innovation process. Data on medical product safety, efficacy, and associated patient outcomes accrued through routine medical practice and through practical research involving a broad range of medical practices could not only bolster our understanding of how well novel treatments are achieving their intended effects, but reinforce many of the premarket reforms currently under consideration. Below and in a new paper, we highlight the importance of postmarket evidence development and present a number of immediately achievable proposals that could help lay the foundation for future cures.

Why is postmarket evidence development important?

There are a number of reasons why evidence developed after a medical product’s approval should be considered an integral part of legislative efforts to improve biomedical innovation. First and foremost, learning from clinical experiences with medical products in large patient populations can allow providers to better target and treat individuals, matching the right drug or device to the right patient based on real-world evidence. Such knowledge can in turn support changes in care that lead to better outcomes and thus higher value realized by any given medical product.

Similarly, data developed on outcomes, disease progression, and associated genetic and other characteristics that suggest differences in disease course or response to treatment can form the foundation of future breakthrough medical products. As we continue to move toward an era of increasingly-targeted treatments, this important of this type of real-world data cannot be discounted.

Finally, organized efforts to improve postmarket evidence development can further establish infrastructure and robust data sources for ensuring the safety and effectiveness of FDA-approved products, protecting patient lives. This is especially important as Congress, the Administration, and others continue to seek novel policies for further expediting the pre-market regulatory review process for high-priority treatments. Without a reliable postmarket evidence development infrastructure in place, attempts to further shorten the time it takes to move a product from clinical development to FDA approval may run up against the barrier of limited capabilities to gather the postmarket data needed to refine a product’s safety and effectiveness profile. While this is particularly important for medical devices – the “life cycle” of a medical device often involves many important revisions in the device itself and in how and by whom it is used after approval – it is also important for breakthrough drugs, which may increasingly be approved based on biomarkers that predict clinical response and in particular subpopulations of patients.

What can be done now?

The last decade has seen progress in the availability of postmarket data and the production of postmarket evidence. Biomedical researchers, product developers, health care plans, and providers are doing more to collect and analyze clinical and outcomes data. Multiple independent efforts – including the U.S. Food and Drug Administration’s Sentinel Initiative for active postmarket drug safety surveillance, the Patient-Centered Outcomes Research Institute’s PCORnet for clinical effectiveness studies, the Medical Device Epidemiology Network (MDEpiNet) for developing better methods and medical device registries for medical device surveillance and a number of dedicated, product-specific outcomes registries – have demonstrated the powerful effects that rigorous, systematic postmarket data collection can have on our understanding of how medical products perform in the real-world and of the course of underlying diseases that they are designed to treat.

These and other postmarket data systems now hold the potential to contribute to data analysis and improved population-based evidence development on a wider scale. Federal support for strengthening the processes and tools through which data on important health outcomes can be leveraged to improve evidence on the safety, effectiveness, and value of care; for creating transparent and timely access to such data; and for building on current evidence development activities will help to make the use of postmarket data more robust, routine, and reliable.

Toward that end, we put forward a number of targeted proposals that current legislative efforts should consider as the 2015 policy agenda continues to take shape:

Evaluate the potential use of postmarket evidence in regulatory decision-making. The initial Cures discussion draft mandated FDA to establish a process by which pharmaceutical manufacturers could submit real-world evidence to support Agency regulatory decisions. While this is an important part of further establishing methods and mechanisms for harnessing data developed in the postmarket space, the proposed timelines (roughly 12 months to first Guidance for Industry) and wide scope of the program do not allow for a thoughtfully-, collaboratively-considered approach to utilizing real-world evidence. Future proposals should allow FDA to take a longer, multi-stakeholder approach to identify the current sources of real-world data, gaps in such collection activities, standards and methodologies for collection, and priority areas where more work is needed to understand how real-world data could be used.

Expand the Sentinel System’s data collection activities to include data on effectiveness. Established by Congress in 2007, Sentinel is a robust surveillance system geared toward monitoring the safety of drugs and biologics. In parallel to the program for evaluating the use of RWE outlined above, FDA could work with stakeholders to identify and pursue targeted extensions of the Sentinel system that begin to pilot collection of such data. Demonstration projects could enable faster and more effective RWE development to characterize treatment utilization patterns, further refine a product’s efficacy profile, or address pressing public health concerns – all by testing strategic linkages to data elements outside of Sentinel’s safety focus.

Establish an active postmarket safety surveillance system for medical devices. Congress has already acted once to establish device surveillance, mandating in 2012 that Sentinel be expanded to include safety data on medical devices. To date, however, there has been no additional support for such surveillance or even the capability of individually tracking medical devices in-use. With the recently finalized Unique Device Identifier rule going effect and the ability to perform such tracking on the horizon, the time is now to adopt recent proposals from FDA’s National Medical Device Postmarket Surveillance System Planning Board. With Congressional authorization for FDA to establish an implementation plan and adequate appropriations, the true foundation for such a system could finally be put into place.

These next steps are practical, immediately achievable, and key to fully realizing the intended effect of other policy efforts aimed at both improving the biomedical innovation process and strengthening the move to value-based health care.

Authors

      




approval

GMO salmon gets final FDA approval

The U.S. Food and Drug Administration has approved the first genetically engineered animal for human consumption.




approval

Court sides with the bees, overturns EPA approval of a pesticide

Appeals court calls EPA approval of bee-threatening sulfoxaflor “based on flawed and limited data.”




approval

EPA catches Dow in weed-killer lie, asks court to reverse approval

The agro giant made contradictory claims to the government about the herbicide Enlist Duo, the EPA isn’t happy.




approval

EPA surprise: Agency seeks to cancel approval of toxic pesticide

And the company that makes the chemical, Bayer CropScience, refuses to agree.




approval

Quid Pro Quo on Keystone approval? Not likely.

As we wait for President Obama and the State Department to make a decision on the proposed Keystone XL pipeline, talk seems to have shifted away from why the pipeline should be rejected to what should be done in the event the project is approved.






approval

A massive renewable energy scheme in Australia has been recommended for environmental approval

Several big firms, including Danish wind turbine manufacturer Vestas, are involved in the project.




approval

Moderna's vaccine candidate could potentially get regulatory approval in 2021

Moderna has received FDA approval for the company's Covid-19 vaccine to continue into the second phase. CNBC's Meg Tirrell reports.




approval

Pharma giants granted coronavirus approvals but doubts remain on manufacturing a global vaccine

Experts warn that vaccine timelines look ambitious and argue more thought is needed on manufacturing.




approval

Gottlieb: Covid-19 vaccine may be available for selective use before official approval

Dr. Scott Gottlieb, member of the boards of Pfizer and biotech company Illumina and former FDA commissioner, tells "Squawk Box" that a Covid-19 vaccine could be made available for use in "selected circumstances" before it receives official approval for wider distribution.




approval

IIT-Delhi develops COVID-19 test kit, gets ICMR's approval

The Indian Institute of Technology (IIT), Delhi has developed a COVID-19 test kit, which has got the approval of Indian Council of Medical Research (ICMR). "We started working on it by the end of January and got it ready in three months. We wanted to contribute to affordable low-cost diagnostics that could be used in large numbers," V Perumal, Professor at IIT-Delhi, told ANI.

Perumal said that it is a swab testing kit. "Testing will be cheaper than all existing devices," he said, adding that the device is affordable for commercial production. ICMR had on Thursday approved detection assay for COVID-19, which has been developed by researchers at IIT-Delhi's Kusuma School of Biological Sciences (KSBS).

"The assay has been validated at the ICMR with a sensitivity and specificity of 100 per cent. This makes IIT-Delhi the first academic institute to have obtained ICMR approval for a real-time PCR-based diagnostic assay," read a statement from IIT-Delhi.

This is the first probe-free assay for COVID-19 approved by the ICMR and it will be useful for specific and affordable high throughput testing. It can easily be scaled up as it does not require fluorescent probes. The team is targeting large-scale deployment of the kit at affordable prices with suitable industrial partners as soon as possible.

Catch up on all the latest Crime, National, International and Hatke news here. Also download the new mid-day Android and iOS apps to get latest updates.

Mid-Day is now on Telegram. Click here to join our channel (@middayinfomedialtd) and stay updated with the latest news

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever




approval

Tax-News.com: Swiss CbC Reporting Regime Wins OECD Approval

Switzerland's country-by-country reporting regime meets international standards and the country effectively exchanges the reports it receives with other countries, an OECD peer review has concluded.




approval

ICMR Gets Approval for Plasma Therapy for COVID-19 Treatment

The Indian Council of Medical Research (ICMR) will conduct trial in 21 hospitals to assess safety and efficacy of convalescent plasma on COVID-19 patients.




approval

United Kingdom Mortgage Approvals

Mortgage Approvals in the United Kingdom decreased to 56.16 Thousand in March from 73.67 Thousand in February of 2020. Mortgage Approvals in the United Kingdom averaged 83.91 Thousand from 1986 until 2020, reaching an all time high of 151.80 Thousand in May of 1988 and a record low of 26.36 Thousand in November of 2008. Mortgage approvals for house purchase refers to the firm offers of lenders to advance credit secured on specific dwellings to their customers. It covers approvals that are fully secured on residential property by a first mortgage. It includes existing borrowers transferring their existing mortgage to another property, lending to first-time purchasers and lending for buy-to-let purposes. This page provides the latest reported value for - United Kingdom Mortgage Approvals - plus previous releases, historical high and low, short-term forecast and long-term prediction, economic calendar, survey consensus and news.




approval

Australia Dwelling Approvals

Building Permits in Australia decreased to -4 percent in March from 19.90 percent in February of 2020. Building Permits in Australia averaged 0.33 percent from 1983 until 2020, reaching an all time high of 31.70 percent in May of 2012 and a record low of -21.90 percent in November of 2002. In Australia, Building Permits show the monthly change in the number of total dwelling units approved, including building activity carried out on existing buildings. This page provides the latest reported value for - Australia Building Permits - plus previous releases, historical high and low, short-term forecast and long-term prediction, economic calendar, survey consensus and news.




approval

Oman Mortgage Approvals

Mortgage Approvals in Oman increased to 1348 in February from 1087 in January of 2020. Mortgage Approvals in Oman averaged 1485.61 from 2011 until 2020, reaching an all time high of 2595 in March of 2016 and a record low of 139 in July of 2017. This page provides - Oman Mortgage Approvals- actual values, historical data, forecast, chart, statistics, economic calendar and news.




approval

Spain Mortgage Approvals

Mortgage Approvals in Spain decreased to 36050 Units in February from 39314 Units in January of 2020. Mortgage Approvals in Spain averaged 52140.30 Units from 2003 until 2020, reaching an all time high of 129128 Units in September of 2005 and a record low of 12146 Units in August of 2013. This page provides - Spain Mortgage Approvals- actual values, historical data, forecast, chart, statistics, economic calendar and news.




approval

Sri Lanka Housing Approvals

Building Permits in Sri Lanka decreased to 2491 in the second quarter of 2019 from 2685 in the first quarter of 2019. Building Permits in Sri Lanka averaged 2866.83 from 1996 until 2019, reaching an all time high of 4505 in the second quarter of 2006 and a record low of 1638 in the second quarter of 2009. This page provides - Sri Lanka Housing Approvals- actual values, historical data, forecast, chart, statistics, economic calendar and news.




approval

Stripe adds card issuing, localized card networks and expanded approvals tool

At a time when more transactions than ever are happening online, payments behemoth Stripe is announcing three new features to continue expanding its reach. The company today announced that it will now offer card issuing services directly to businesses to let them in turn make credit cards for customers tailored to specific purposes. Alongside that, it’s going […]




approval

Neymar gives his approval to mother's relationship with 22-year-old computer game fan

Nadine Goncalves is dating model Tiago Ramos and posted a loving photo of the couple on Instagram, despite Ramos being six years Neymar's junior.




approval

Cody Simpson's mother Angie gives her tick of approval to his blossoming romance with Miley Cyrus

Cody Simpson's mother Angie appears to have given her tick of approval on her son's new love Miley Cyrus.




approval

Trump THANKS AOC for boosting approval rating in hat-tip to 'vicious young Socialist congresswomen' 

Donald Trump attributed his Wednesday approval rating boost to the recent controversy with Alexandria Ocasio-Cortez and the rest of the freshmen 'squad' of congresswomen.




approval

Magda Szubanski gives her seal of approval as her Kath & Kim character gets her own post stamp

She recently brought her hilarious Kath & Kim character Sharon Strzelecki back to life, appearing in a series of UberEats commercial with Kim Kardashian.




approval

Top White House officials shelved guidance for reopening the US despite CDC approval

Top White House officials shelved expert guidance to reopening America from the Centers for Disease Control and Prevention, despite the report being greenlit by the CDC director, the Associated Press reported.The first 17 pages of the report — which spanned more than 60 pages — was initially released by the AP on May 7, after the White House killed its release on April 30, the day federal social distancing guidelines were set to expire.Following the AP report on Thursday, the White House subsequently fast-tracked the approval for release of the guidance.White House spokeswoman Kayleigh McEnany told reporters Friday that the report was not released because CDC director Robert Redfield had not approved of it. However, internal emails obtained by the AP suggest a different timeline.Visit Business




approval

Seal meets Delta Goodrem's mum for tick of approval

According to another report in the magazine, the duo 'have discussed plans for kids, with Seal meeting Delta's mother Lea to get her tick of approval'.




approval

Arnold Schwarzenegger mocks Donald Trump's approval rating

Arnold Schwarzenegger tweeted a video on Tuesday deriding Donald Trump in the wake of the president's latest approval rating, which Gallup reported on Sunday as being at 39%.




approval

Donald Trump touts his '95 per cent approval rating' from Republicans

President Trump's attention turned back to his poll numbers Saturday, as he arrived at his Trump International Golf Club in West Palm Beach.




approval

Biden insists ALL president's approval ratings go up during crisis in downplaying Trump's surge

Joe Biden downplayed Donald Trump's approval rating boost during the coronavirus outbreak, claiming all president's have seen a surge during times of crisis in the U.S.




approval

FDA gives emergency approval to Roche's coronavirus antibody blood test

Swiss drug maker Roche says its coronavirus antibody blood test has a specificity rate of 99.8% and a sensitivity of 100%, meaning it would show very few false positives and no false negatives




approval

IFAB chief Lukas Brud says Arsene Wenger's plans for offside law 'is not up for approval'

International Football Association Board's Lukas Brud has revealed that Wenger's proposed major overhaul of the law is not an option and the offside rule will remain the same.




approval

Credit card approvals will fall and interest-free terms will shrink

The Bank of England's latest credit conditions survey revealed lenders believe the availability of household unsecured credit will decrease between April and June amid coronavirus.




approval

Expert panel giving conflicted IPR approvals


Many of the institutions or departments who have sent in applications for IPR consideration to the NBA are also represented on the committee which evaluates the applications, reports Kanchi Kohli.




approval

Old approvals from a new regulator?


The SC orders the government to constitute an independent environmental regulatory authority. While the flaws in the current arrangement are plain, it is not clear if independence of the regulator alone can address these, writes Kanchi Kohli.




approval

Build first, sell next, approvals later


The private sector Baspa II hydel power project went live over two and half years ago and has been selling power to the Himachal Pradesh State Electricity Board. Lack of regulatory approvals and determination of final wholesale tariff has not deterred the company from raising money in capital markets. Himanshu Upadhyaya finds out more.




approval

NASA VITAL Ventilators Get FDA Approval To Fight COVID-19

As the coronavirus pandemic continued sweeping across the globe, NASA put a halt on its usual space-related activities and began developing a prototype ventilator to help combat the deadly virus. The newly developed ventilator has just received emergency approval from the




approval

Automobile Component Manufacturers In Green Zone To Restart Operations Soon: Awaiting Approval

The Indian auto industry is slowly working its way to restart operations in India, after being shut down for over 40 days. Automobile companies are currently preparing to resume production in accordance with the government's guidelines for ensuring all safety and social distancing norms are followed.




approval

ECB/FCCB approvals decline 31 per cent to $5,564 million during Q1

ECB/FCCB approvals decline 31 per cent to $5,564 million during Q1




approval

Crystalline silicon terrestrial photovoltaic (PV) modules : design qualification and type approval




approval

Thin-film terrestrial photovoltaic (PV) modules : design qualification and type approval = Modules photovoltaïques (PV) en couches minces pour application terrestre : qualification de la conception et homologation




approval

Fast-track green approvals for 795 MT coal output in 2012-17: Eco Survey

Delays in environment clearances needs to be addressed on a fast-track basis for achieving coal production target of 795 MT during the current five year plan (2012-17), the Economic Survey said today.




approval

Angry Nerd - Chris Baker Defends His Disapproval of Zynga Board Games

Chris Baker got Angry and Nerdy about Zynga making board games out of online games out of board games. Commenters commented. Baker defends his purchase of said games. And gets Angry.